Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Core Insights - Eli Lilly and Co. released topline results from the SURPASS-CVOT trial, showing that Mounjaro (tirzepatide) demonstrated a non-inferior rate of major adverse cardiovascular events (MACE-3) compared to Trulicity (dulaglutide) [1][3] Group 1: Trial Results - Mounjaro achieved the primary objective of non-inferiority in MACE-3, which includes cardiovascular death, heart attack, or stroke, with an 8% lower risk compared to Trulicity [3] - The trial enrolled over 13,000 participants and lasted more than four and a half years, making it the largest and longest study of tirzepatide to date [3] - Mounjaro showed a 16% lower all-cause mortality rate compared to Trulicity [4] Group 2: Additional Findings - Mounjaro demonstrated improvements in key measures such as A1C, weight, renal function, and all-cause mortality, although these results were not controlled for multiplicity-adjusted type-1 error [2][6] - An indirect comparison analysis indicated that Mounjaro reduced the risk of MACE-3 by 28% and all-cause mortality by 39% compared to a hypothetical placebo [4] Group 3: Safety and Tolerability - The safety and tolerability profiles of Mounjaro and Trulicity were generally consistent with established data, with 13.3% of Mounjaro participants discontinuing treatment due to adverse events, compared to 10.2% for Trulicity [6] - Mounjaro improved cardiovascular biomarkers, including lipids and systolic blood pressure, compared to Trulicity [6] Group 4: Regulatory Plans - Eli Lilly plans to submit the trial data to global regulatory authorities by the end of the year [6]